Mia's Feed
Medical News & Research

The Role of MASLD in Increasing Liver Cancer Risk Post-HCV Treatment

The Role of MASLD in Increasing Liver Cancer Risk Post-HCV Treatment

Share this article

New research shows MASLD significantly increases the risk of hepatocellular carcinoma after hepatitis C cure. Effective management of metabolic health is crucial for liver cancer prevention post-treatment.

2 min read

Recent studies have highlighted the significant impact of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) on the development of hepatocellular carcinoma (HCC) even after successful hepatitis C virus (HCV) eradication. MASLD is diagnosed when steatotic liver disease (SLD) coexists with at least one cardiometabolic risk factor (CMRF), such as obesity, hypertension, type 2 diabetes, or dyslipidemia.

A multicenter research effort in Taiwan involving 1,598 participants tracked these individuals for a median of five years after they received direct-acting antivirals (DAAs) to cure HCV. The findings revealed that patients with MASLD faced roughly double the risk of developing HCC compared to those without MASLD, even after accounting for age, sex, liver stiffness, platelet count, liver enzyme levels, and alpha-fetoprotein. The risk remained consistent when considering other causes of mortality, emphasizing the persistent threat posed by MASLD.

Furthermore, nearly all individuals with steatotic liver disease also had MASLD, underscoring the close link between metabolic health and liver disease progression. The study also indicated that MASLD mediates several CMRFs that contribute to carcinogenesis, highlighting its central role in HCC development.

Experts suggest that, although the incidence of HCC tends to decline following viral cure, continued reliance on vigilant screening and management of metabolic risk factors is essential. Lifestyle modifications and effective control of conditions like obesity, diabetes, and hypertension should be prioritized. Additionally, emerging therapies targeting the liver microenvironment, such as thyroid hormone receptor beta (THRβ) agonists, may offer new avenues to reduce HCC risk.

In conclusion, managing MASLD and associated metabolic derangements is vital for reducing liver cancer risk in patients cured of HCV, emphasizing a comprehensive approach that includes lifestyle adjustments and targeted therapies.

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Pediatrician Warns that Banning Fluoride in Public Water Systems Jeopardizes Kids' Oral Health in Rural and Low-Income Communities

Legislation banning fluoride in public water supplies threatens to increase dental cavities among children in rural and low-income communities, warns pediatrician. Experts emphasize the importance of water fluoridation for preventing childhood cavities, especially where dental care access is limited.

Rising Threat of Synthetic Opioids in Australia

Australia faces an emerging threat from highly potent synthetic opioids like nitazenes, which are contaminating the drug supply and increasing overdose risks. Enhanced monitoring and harm reduction strategies are urgently needed.

Rising Alcohol-Related Cancer Deaths in the United States

A new study highlights the alarming rise in alcohol-related cancer deaths in the US, emphasizing the need for increased awareness and preventative strategies to combat this growing health threat.